Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels

被引：18

作者：

Jolly, M. ^{[1
]}

Galicier, L. ^{[2
,3
]}

Aumaitre, O. ^{[4
,5
]}

Frances, C. ^{[6
,7
]}

Le Guern, V. ^{[8
,9
]}

Liote, F. ^{[2
,10
]}

Smail, A. ^{[11
]}

Limal, N. ^{[12
,13
]}

Perard, L. ^{[14
]}

Desmurs-Clavel, H. ^{[14
]}

Boutin, D. L. T. H. ^{[6
,15
]}

Asli, B. ^{[2
,3
]}

Kahn, J-E ^{[16
]}

Pourrat, J. ^{[17
,18
]}

Sailler, L. ^{[17
,19
]}

Ackermann, F. ^{[16
]}

Papo, T. ^{[2
,20
]}

Sacre, K. ^{[2
,20
]}

Fain, O. ^{[21
]}

Stirnemann, J. ^{[22
]}

Cacoub, P. ^{[23
,24
,25
]}

Jallouli, M. ^{[8
,9
]}

Leroux, G. ^{[6
,15
]}

Cohen-Bittan, J. ^{[26
]}

Hulot, J-S ^{[27
]}

Arora, S. ^{[1
]}

Amoura, Z. ^{[6
,15
]}

Piette, J-C ^{[6
,15
]}

Costedoat-Chalumeau, N. ^{[8
,9
]}

机构：

[1] Rush Univ, Med Ctr, 1611 W Harrison St,Suite 510, Chicago, IL 60612 USA

[2] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France

[3] Hop St Louis, AP HP, Serv Immunol Clin, Paris, France

[4] Univ Clermont Ferrand, Clermont Ferrand, France

[5] CHU Clermont Ferrand, Hop Gabriel Montpied, Serv Med Interne, Clermont Ferrand, France

[6] Univ Paris 06, Paris, France

[7] Hop Tenon, AP HP, Serv Dermatol Allergol, F-75970 Paris, France

[8] Univ Paris Decartes, Paris, France

[9] Hop Cochin, AP HP, Serv Med Interne, F-75014 Paris, France

[10] Hop Lariboisiere, AP HP, Serv Rhumatol, F-75475 Paris, France

[11] CHU Amiens, Hop Nord, Serv Med Interne, Amiens, France

[12] UPEC, Creteil, France

[13] Hop Henri Mondor, AP HP, Serv Med Interne, F-94010 Creteil, France

[14] Hosp Civils Lyon, Grp Hosp Edouard Herriot, Serv Med Interne, Lyon, France

[15] Hop La Pitie Salpetriere, AP HP, Serv Med Interne, Paris, France

[16] Hop Foch, Serv Med Interne, Suresnes, France

[17] Univ Toulouse 3, F-31062 Toulouse, France

[18] CHU Toulouse, Hop Rangueil, Serv Nephrol, Toulouse, France

[19] CHU Toulouse, Hop Purpan, Serv Med Interne, Toulouse, France

[20] Hop Bichat Claude Bernard, AP HP, Serv Med Interne, Paris, France

[21] Univ Paris 06, DHU i2B, Hop St Antoine, Serv Med Interne, Paris, France

[22] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland

[23] Grp Hosp Pitie Salpetriere Paris, AP HP, Dept Med Interne & Immunol Clin, Paris, France

[24] Univ Paris 06, DHU Inflammat Immunopathol Biotherapie, Paris 4, France

[25] Univ Paris 06, UMR 7211, CNRS, UMR S 959,INSERM, Paris, France

[26] Hop La Pitie Salpetriere, AP HP, Serv Geriatrie Pr Verny, Paris, France

[27] Univ Paris 06, Sorbonne Univ, AP HP, Inst Cardiometabolism & Nutr ICAN, F-75013 Paris, France

来源：

LUPUS | 2016年 / 25卷 / 07期

关键词：

Hydroxychloroquine; quality of life; patient reported outcomes; systemic lupus erythematosus; blood concentration; RHEUMATOID-ARTHRITIS; IMPROVING ADHERENCE; SURVIVAL; MARKER; ADULTS; TIME;

D O I：

10.1177/0961203315627200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives Benefits of hydroxychloroquine (HCQ) use on physician reported outcomes are well documented in systemic lupus erythematosus (SLE). We assess for the first time the association and predictive value of blood HCQ levels towards health-related quality of life (HRQOL) in SLE. Methods Data from the PLUS study (a randomized, double-blind, placebo-controlled, multicentre study) were utilized. Blood HCQ levels were quantified by high-performance liquid chromatography along with HRQOL assessments (Medical Outcomes Study-SF-36) at baseline (V1) and month 7 (V2). Results 166 SLE patients' data were analysed. Mean (SD) age and disease duration were 44.4 (10.7) and 9.3 (6.8) years. Eighty-seven per cent were women. Mean (SD, median, IQR) HCQ concentrations in the blood at V1 were 660 (314, 615, 424) ng/ml and increased to 1020 (632, 906, 781) ng/ml at V2 (mean difference 366 units, 95% confidence interval -472 to -260, p<0.001). No significant correlations between HCQ concentrations with HRQOL domains at V1 or V2 were noted. There were no differences in HRQOL stratified by HCQ concentrations. HCQ concentrations at V1 or changes in HCQ concentration (V2-V1) were not predictive of HRQOL at V2 or changes in HRQOL (V2-V1). Conclusions No association of HCQ concentrations with current or longitudinal HRQOL were found in SLE.

引用

页码：735 / 740

页数：6

共 26 条

[1] Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus [J].

Aggarwal, Rohit ;

Wilke, Caitlyn T. ;

Pickard, A. Simon ;

Vats, Vikrant ;

Mikolaitis, Rachel ;

Fogg, Lewis ;

Block, Joel A. ;

Jolly, Meenakshi .

JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) :1209-1216

[2] Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus:: Data from LUMINA, a multiethnic US cohort (LUMINA L) [J].

Alarcon, Graciela S. ;

McGwin, Gerald ;

Bertoli, Ana M. ;

Fessler, Barri J. ;

Calvo-Alen, Jaime ;

Bastian, Holly M. ;

Vila, Luis M. ;

Reveille, John D. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1168-1172

[3]

Alexander S, 2013, J AM SOC NEPHROL

[4] Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus [J].

Costedoat-Chalumeau, Nathalie ;

Amoura, Zahir ;

Hulot, Jean-Sebastien ;

Aymard, Guy ;

Leroux, Gaelle ;

Marra, Donata ;

Lechat, Philippe ;

Piette, Jean-Charles .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :821-824

[5] Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus [J].

Costedoat-Chalumeau, Nathalie ;

Amoura, Zahir ;

Hulot, Jean-Sebastien ;

Abou Hammoud, Hala ;

Aymard, Guy ;

Cacoub, Patrice ;

Frances, Camille ;

Wechsler, Bertrand ;

Huong, Du Le Thi ;

Ghillani, Pascale ;

Musset, Lucile ;

Lechat, Philippe ;

Piette, Jean-Charles .

ARTHRITIS AND RHEUMATISM, 2006, 54 (10) :3284-3290

[6]

Costedoat-Chalumeau N, 2014, ARTHRITIS RHEUMATOL, V66, P770, DOI 10.1002/art.38243

[7] Adherence to treatment in systemic lupus erythematosus patients [J].

Costedoat-Chalumeau, Nathalie ;

Pouchot, Jacques ;

Guettrot-Imbert, Gaelle ;

Le Guern, Veronique ;

Leroux, Gaelle ;

Marra, Donata ;

Morel, Nathalie ;

Piette, Jean-Charles .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2013, 27 (03) :329-340

[8] Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) [J].

Costedoat-Chalumeau, Nathalie ;

Galicier, Lionel ;

Aumaitre, Olivier ;

Frances, Camille ;

Le Guern, Veronique ;

Liote, Frederic ;

Smail, Amar ;

Limal, Nicolas ;

Perard, Laurent ;

Desmurs-Clavel, Helene ;

Boutin, Du Le Thi Huong ;

Asli, Bouchra ;

Kahn, Jean-Emmanuel ;

Pourrat, Jacques ;

Sailler, Laurent ;

Ackermann, Felix ;

Papo, Thomas ;

Sacre, Karim ;

Fain, Olivier ;

Stirnemann, Jerome ;

Cacoub, Patrice ;

Jallouli, Moez ;

Leroux, Gaelle ;

Cohen-Bittan, Judith ;

Tanguy, Marie-Laure ;

Hulot, Jean-Sebastien ;

Lechat, Philippe ;

Musset, Lucile ;

Amoura, Zahir ;

Piette, Jean-Charles .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (11) :1786-1792

[9] Top 10 Recent Developments in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus [J].

Dua, Anisha B. ;

Touma, Zahi ;

Toloza, Sergio ;

Jolly, Meenakshi .

CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (12)

[10] Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence [J].

Durcan, Laura ;

Clarke, William A. ;

Magder, Laurence S. ;

Petri, Michelle .

JOURNAL OF RHEUMATOLOGY, 2015, 42 (11) :2092-2097

← 1 2 3 →